Overall verdict
Neutral
6.2/10
1-year performance
+5.17%
Score breakdown
Up 5.2% over 1 year, 79% of the 52-week range.
Strongest: Profitability 7.5/10. Weakest: Shareholder return 1.7/10.
24 analysts, target +0.2% vs the price.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.
Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Six
Switzerland
CEO
Dr. Wolfgang Wienand Ph.D.
Founded
1897
Employees
16 866
Revenue / employee
387 229 CHF
Next earnings
October 28, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
597.80 CHF
52-week low
454.60 CHF
1-year performance
5.17%
Rising
Year-to-date performance
6.08%
Rising
Drawdown
-5.02%
Mild pullback
Position in the 52-week range
79% of range
Range: 550.00 CHF - 805.11 CHF (2 methods agree)
The price implies growth of 34.80% per year; the company grows at 7.70%.
Gross margin 36.5%, the company loses 4.2% of its revenue, ROIC 8.7%, ROE 12.6%.
Net margin
-4.21%
Negative
Sector 5.47%|S&P 12.97%
Gross margin
36.53%
Fair
Return on equity (ROE)
12.64%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
8.70%
Exceptional
Free cash flow margin (FCF)
3.40%
Low
Margin stability
14.4 pts
Very uneven
Revenue to net income
Growth
4.8/10Revenue up 11.2% over 1 year, 7.7% a year over 5.
Revenue (trailing 12 months)
6.2Md CHF
Revenue growth (1y)
11.20%
Strong
Revenue growth (3y)
4.95%
Moderate
EPS growth (1y)
39.20%
Strong
EPS CAGR (5y)
—
EPS revisions (3 months)
2.59%
Revised up
Valuation
4.9/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 50.6x|S&P 23.0x
Forward P/E
33.2x
Fair
EV / EBITDA
20.0x
Fair
Sector 28.4x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
637.87 CHF
Undervalued
P/E vs its own 5-year history
among the 35% highest valuations
Pricier than usual
Market cap
38.4Md CHF
Financial strength
6.3/10Cash covers 11.7% of the debt, net debt/EBITDA 1.9x.
Net debt / EBITDA
1.9x
Tight
Gearing (net debt / equity)
45.14%
Solid
Cash
478M CHF
Cash / market cap
1.24%
Stretched
Cash / total debt
11.69%
Stretched
Net debt
3.6Md CHF
Equity
8.0Md CHF
Closed daily candles, 2 years
Last close on September 24, 2026: 570.00 CHF
- MM20556.77
- MM50564.12
- MM200530.13
- RSI 1458.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.33%
200-day average slope, 3 months
+1.25%
50-day average slope, 1 month
+0.38%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.30 % per day
Volatility change
-5.72%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 17.11 (20) | 18.53 (17) | 7 129 (23) | 2 380 (20) | 1 219 (16) |
| 2027 | 20.48 (20) | 22.06 (18) | 7 953 (23) | 2 709 (21) | 1 437 (16) |
Amounts in millions of CHF, EPS in CHF per share. In brackets, the number of analysts. Consensus as of September 16, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | A | 6.5 | 6.9 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 5 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 6 | LONN | 6.2 | 5.4 | 46.4Md USD | Not meaningful (loss) | -4.2 % | 11.2 % | 8.7 % | 1.9x | 0.5 % | 5.2 % | ||
| 7 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 4.9 | 5.1 | 38.6Md USD | 47.6x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 175.3 % | ||
| 9 | WAT | 4.7 | 3.7 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
